Steward Partners Investment Advisory LLC Sells 1,241 Shares of Organon & Co. (NYSE:OGN)

Steward Partners Investment Advisory LLC trimmed its holdings in Organon & Co. (NYSE:OGNFree Report) by 11.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,920 shares of the company’s stock after selling 1,241 shares during the period. Steward Partners Investment Advisory LLC’s holdings in Organon & Co. were worth $148,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Prospera Private Wealth LLC acquired a new stake in Organon & Co. in the 3rd quarter worth approximately $25,000. Horizon Bancorp Inc. IN raised its position in shares of Organon & Co. by 2,401.5% in the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock valued at $25,000 after purchasing an additional 1,585 shares during the period. Riverview Trust Co lifted its stake in shares of Organon & Co. by 117.7% in the fourth quarter. Riverview Trust Co now owns 2,390 shares of the company’s stock worth $36,000 after buying an additional 1,292 shares during the last quarter. Versant Capital Management Inc boosted its holdings in shares of Organon & Co. by 92.2% during the 4th quarter. Versant Capital Management Inc now owns 2,760 shares of the company’s stock worth $41,000 after buying an additional 1,324 shares during the period. Finally, MassMutual Private Wealth & Trust FSB grew its stake in Organon & Co. by 32.4% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock valued at $41,000 after buying an additional 672 shares during the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on OGN. Morgan Stanley cut their target price on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a research report on Friday, February 14th. TD Cowen raised Organon & Co. to a “hold” rating in a research report on Wednesday, January 15th. Finally, Barclays decreased their target price on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $20.80.

Get Our Latest Analysis on OGN

Organon & Co. Stock Up 2.5 %

Shares of OGN opened at $15.34 on Monday. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. The company has a 50-day simple moving average of $15.46 and a 200-day simple moving average of $16.64. Organon & Co. has a 52 week low of $13.87 and a 52 week high of $23.10. The firm has a market capitalization of $3.96 billion, a P/E ratio of 4.61, a P/E/G ratio of 0.90 and a beta of 0.76.

Organon & Co. (NYSE:OGNGet Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The firm had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. On average, equities research analysts expect that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were given a $0.28 dividend. The ex-dividend date was Monday, February 24th. This represents a $1.12 annualized dividend and a yield of 7.30%. Organon & Co.’s dividend payout ratio (DPR) is currently 33.63%.

About Organon & Co.

(Free Report)

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Featured Stories

Institutional Ownership by Quarter for Organon & Co. (NYSE:OGN)

Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.